To identify therapeutic vulnerabilities specific to MYCN-driven retinoblastoma, we assessed drug sensitivity profiles of MYCN-overexpressing cells (MYCNO/E-cells) derived from retinal organoids compared with the established retinoblastoma cell line Y79 (RB1−/−, MYCN-amplified). The gene discussed is MYCN; the disease is retinoblastoma.